ABA Editorial · Oct 27, 2025 · 14 min read
Diagnostic capacity is one of the most binding constraints in African healthcare, with most rural facilities lacking basic laboratory equipment and trained technicians. Ilara Health has deployed affordable diagnostic equipment to underserved healthcare providers in Kenya and Uganda with USD 13 million in cumulative funding. The collapse of 54gene illustrated the difficulty of building genomics at commercial scale. This report maps the diagnostics landscape.
Diagnostic capacity is one of the most binding constraints in African healthcare. A physician who cannot order laboratory tests, imaging, or point-of-care diagnostics is limited to clinical assessment based on symptoms and physical examination, which misses many conditions that would be straightforward to identify with appropriate testing. African diagnostic infrastructure is concentrated in urban centers and national referral hospitals, with most rural and peri-urban facilities lacking basic laboratory equipment, trained technicians, or reliable reagent supply chains. Even where equipment exists, it is often non-functional due to maintenance gaps, missing consumables, or workforce turnover that leaves facilities unable to operate their installed capacity. This report maps the African diagnostics and point-of-care landscape, the operators attempting to close the gaps, and the lessons from high-profile failures including the collapse of 54gene.
Ilara Health, operating in Kenya and Uganda, has built a distinctive business around deploying affordable diagnostic equipment to healthcare providers in underserved areas. The company provides a network of ultrasound machines, X-ray machines, and laboratory equipment to clinics and small hospitals that could not otherwise afford these capabilities through conventional procurement. Ilara also trains healthcare providers to use the equipment effectively, which addresses the workforce capability gap that has historically undermined diagnostic equipment deployments in African contexts. The company has raised approximately USD 13 million in cumulative funding across multiple rounds.
Through 2024 and 2025, Ilara Health restructured its operations and laid off staff despite closing a USD 4.2 million round in the preceding period. The restructuring reflects the same pressures that affected the broader African healthtech sector: commercial unit economics in underserved markets are harder than initial thesis assumptions often suggested, and operators who built infrastructure during the pandemic-era enthusiasm have had to adapt to a more capital-constrained environment. The Ilara core operational model (deploying equipment to underserved providers on affordable terms, supporting use through training, and generating revenue through usage fees or service contracts) remains intact even as the company has adjusted its scale and organization.
54gene was one of the most visible African health companies of its time. Founded in Nigeria with ambitions to build African genomics capacity, the company raised significant venture capital and attracted international attention for its vision of addressing the under-representation of African populations in global genomic databases. The company collapsed through a difficult period that included staff departures, operational restructuring, and ultimately the shutdown of its primary business lines.
The 54gene experience offers several lessons for African diagnostic operators. First, genomics specifically is a capital-intensive category that requires sustained long-term investment before commercial returns can be realized. Second, African commercial markets may be too small and fragmented to support genomics business models that assume substantial domestic demand for specialized services. Third, the gap between research narrative (the compelling case for African genomic representation) and commercial execution (building a sustainable business that can actually deliver genomic services at scale) can be larger than investors anticipate during fundraising. The broader category of African health startups attempting to build research-driven business models has had to absorb these lessons.
Point-of-care diagnostics (tests that can be performed at the location of patient care rather than requiring transport to a central laboratory) are particularly well-suited to African conditions where centralized laboratory infrastructure is limited. Malaria rapid diagnostic tests, HIV rapid tests, blood glucose monitors, and similar technologies have been deployed at scale across African health systems for specific disease categories. More recent additions including SARS-CoV-2 tests during the COVID-19 pandemic demonstrated that rapid diagnostic capacity can be scaled up in response to specific health priorities when adequate funding is available.
The broader opportunity for point-of-care diagnostics includes expanding the test categories available at rural facilities, improving the quality assurance framework to ensure reliable results, and integrating test results into clinical decision-making and health information systems. Several African operators have been working on these expansions, though the commercial unit economics often depend on donor financing or public-sector procurement rather than pure commercial demand.
Centralized laboratory infrastructure in African countries is typically concentrated in capital cities and major referral hospitals, with limited capacity at regional and district levels. The result is that samples from peripheral facilities often must travel significant distances to reach laboratories capable of processing them, with delays and sample quality issues that undermine diagnostic reliability. Several donor-financed programs have invested in building regional laboratory networks, but the coverage remains uneven and the sustainability of donor-financed capacity after project completion is often a concern.
Digital laboratory management systems have emerged as one component of the response, providing the information infrastructure that allows existing laboratories to operate more efficiently and to coordinate with clinical providers across their service areas. These systems do not address the underlying physical capacity gap, but they can improve the utilization of existing capacity, which is often below what could be achieved with better coordination.
Medical imaging (X-ray, ultrasound, CT, MRI) is particularly limited in African healthcare outside major urban centers. CT and MRI machines are concentrated at national referral hospitals in capital cities, meaning that patients in other parts of the country must travel long distances or forgo these diagnostic modalities entirely. Ultrasound, which is cheaper and more portable than larger imaging equipment, has been more widely deployed but still lags global norms for coverage. Ilara Health's ultrasound deployment model is one of the more visible responses to this gap.
Teleradiology (remote interpretation of imaging by radiologists who may be in different countries) has been explored as a partial response to the radiologist shortage. African radiologist counts are low, and the radiologists who do practice are concentrated in urban centers. Teleradiology allows a patient in a rural area to receive an imaging study that is then interpreted by a radiologist located elsewhere, extending the reach of the scarce specialist workforce.
Three indicators will shape African diagnostics and point-of-care. First, whether Ilara Health's restructured operations demonstrate durable unit economics that would validate its equipment-deployment model for extension to additional markets. Second, whether point-of-care diagnostic deployment continues to expand across additional disease categories and geographies, closing specific diagnostic gaps that undermine clinical care. Third, whether digital infrastructure for laboratory management and teleradiology continues to develop, extending the reach of the specialist workforce through technology. Diagnostics capacity is the foundation of effective clinical care, and its expansion in African contexts is one of the highest-leverage investments available for improving health outcomes.